Navigation Links
Pescatello Elected to Head New England Biotech Association in 2011-12
Date:1/18/2011

WAKEFIELD, Mass., Jan. 18, 2011 /PRNewswire/ -- Paul Pescatello has been re-elected as Chairman of the New England Biotech Association (NEBA) at the organization's annual meeting.

NEBA is a non-profit, member-driven organization comprised of state biotech associations, companies, academic institutions, and other organizations in the six New England states with a collective mission to support and grow the biotechnology industry in the region, and serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical industry.

Pescatello is President & CEO of CURE (Connecticut United for Research Excellence) the educational and business support network organization for bioscience in Connecticut, and will serve a two-year term as head of NEBA.  Pescatello served as NEBA Chairman in 2010 and has been a member of the board since the group's founding.  

"2011 brings with it many changes and challenges for the biotechnology and biopharmaceutical industry," said Pescatello.  "With new governors and legislatures in many New England states, it is critical that NEBA continues to educate our policy leaders about biotech and help create a positive regional environment for retention and growth."

"One of our priorities of the upcoming year will be to explore and explain the impact of national Health Care Reform Implementation and its impact on the biotech and biopharmaceutical industries in the six New England states," Pescatello continued.  "Clearly, NEBA can play a role in helping our members--as well as policy leaders and the public--better understand what it will mean for jobs and discovery in the biosciences field."

Representing over 600 members from all six New England states, NEBA is committed to educating policy makers and the public about the biotech industry; promoting public policies that foster innovation; encouraging economic development in the biotech sector; and advocating cont
'/>"/>

SOURCE New England Biotech Association
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... S.C., Oct. 21, 2011 Federal, state and local ... growing biomedical research effort with the dedication of a ... for major diseases. The complex, housing 78 ... traditional research approach by combining scientists from different fields ...
... division of Sanofi (EURONEXT: SAN and NYSE: ... study evaluating the immunogenicity and safety of an investigational ... of age and older. Currently licensed influenza vaccines target ... a given year. The data were presented at the ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
(Date:5/21/2013)... Adenotonsillectomy, or the removal of the adenoids and tonsils, ... States, often as a treatment for children with obstructive ... a child,s attention and executive functioning, behavior, sleep apnea ... evaluated until now. A study led by Susan ... Sleep and Cardiovascular Medicine and Associate Clinic Director of ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2
... and other headaches are more likely to have retinopathy, damage ... severe vision problems or blindness, than those without a ... May 15, 2007, issue of Neurology, the scientific journal of ... researchers reviewed the headache history and eye health of 10,902 ...
... and chronic obstructive pulmonary disease among men has discovered ... progressive inflammatory lung disease (COPD). ,COPD (chronic ... progressive lung disease, such as emphysema and bronchitis. ... 43,000 men, who were already part of the US ...
... of infant mortality, cancer, accidental death, and diabetes than any ... according to a state health official, the Sioux Falls Argus ... Health Department, at the request of the Zaniya Task Force, ... of the state's population and found what he called "very ...
... increase the risk of heart attacks and death in patients who ... caused by plaque build-up on the inside walls of the arteries ... them to harden and narrow. This in addition, can ... , According to a report in the Journal of ...
... new research has found that extremely anxious patients with heart ... death when compared to those with a calmer attitude ... were in greatest danger, while those who initially had high ... risk. ,"Most patients come in very anxious about ...
... lay along the Nile in ancient Egypt and not ... the KNH Centre for Biomedical Egyptology at the ... team discovered the evidence in medical papyri written in ... ,"Classical scholars have always considered the ancient Greeks, ...
Cached Medicine News:Health News:Mid-Life Headaches May Increase Risk of Vision Problems 2Health News:American Indians in South Dakota Have More Health Problems Than Others in State, Nationwide, Health Official Says 2Health News:Dont Worry- Be Good To Your Heart 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 3Health News:Modern Medicine Originated in Egypt, Not Greece 2
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: